Plus   Neg

Stock Alert: Baidu Rises 9% After Reporting Upbeat Results

Shares of Baidu, Inc. (BIDU), Chinese technology company specializing in Internet-related services and products and artificial intelligence, are climbing more than 9% Tuesday morning on the back of upbeat first-quarter results.

"In March, a month after the peak of COVID-19 new cases, Baidu's traffic remained robust with Baidu App DAUs reaching 222 million, up 28% year over year, in-app search queries up 45% and feed time spent up 51%. With the pandemic coming under control in China, offline activities are rebounding and Baidu stands to benefit from a restart of the Chinese economy, " said Robin Li, Co-founder, and CEO of Baidu.

Adjusted earnings of $1.25 per ADS for the first quarter beat the average estimate of analysts polled by Thomson Reuters at $0.57.

Revenues were RMB 22.5 billion ($3.18 billion), decreased 7% year over year. The consensus estimate was at $3.1 billion.

For the second quarter of 2020, Baidu expects revenues to be between RMB 25.0 billion ($3.5 billion) and RMB 27.3 billion ($3.9 billion). Analysts see revenue of $3.62 billion.

Baidu stock is currently trading at $117.35. It has traded in the range of $82.00- $147.38 in the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. auto safety regulator has opened an investigation into about 115,000 Tesla electric vehicles over a front suspension safety issue. The probe covers 2015 through 2017 Model S sedans and 2016 through 2017 Model X SUVs. The investigation comes after Tesla reportedly started a recall over the issue for vehicles in China. Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform
Follow RTT